Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

31.48USD
1:45pm EST
Change (% chg)

$-0.11 (-0.35%)
Prev Close
$31.59
Open
$31.63
Day's High
$31.70
Day's Low
$31.43
Volume
1,842,555
Avg. Vol
6,302,602
52-wk High
$37.39
52-wk Low
$28.25

PFE.N

Chart for PFE.N

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $191,578.00
Shares Outstanding(Mil.): 6,068.35
Dividend: 0.30
Yield (%): 3.80

Financials

  PFE.N Industry Sector
P/E (TTM): 31.52 29.13 29.87
EPS (TTM): 1.00 -- --
ROI: 4.34 15.56 14.95
ROE: 9.51 16.69 16.29

AstraZeneca pill slashes lung cancer progression in study

LONDON AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's lofty long-term sales goals.

5:07am EST

Pfizer blood cancer drug tops standard therapy for untreated patients

Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production.

Dec 05 2016

GSK insider Waterhouse to head drugmaker's HIV unit ViiV

LONDON GlaxoSmithKline said on Monday that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse.

Dec 05 2016

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study.

Nov 30 2016

BRIEF-FDA accepts the Biologics' license application for Avelumab for priority review

* FDA accepts the biologics license application for Avelumab for the treatment of metastatic merkel cell carcinoma for priority review

Nov 29 2016

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

Nov 29 2016

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT, Nov 29 German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

Nov 29 2016

French cancer specialist Innate Pharma can remain independent, for now: CEO

PARIS France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April.

Nov 25 2016

BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe

* Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe Source text for Eikon: Further company coverage:

Nov 22 2016

Pfizer sues Texas health agency for releasing confidential information

Pfizer Inc has sued Texas' health agency, claiming it violated state and federal law by releasing the company's confidential Medicaid rebate information to two state senators.

Nov 18 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $112.00 +0.06
Novartis AG (NOVN.S) CHF69.35 -0.15
Merck & Co., Inc. (MRK.N) $59.99 -0.25
Roche Holding Ltd. (ROG.S) CHF222.50 +0.40
Roche Holding Ltd. (RO.S) CHF226.50 +0.50
Abbott Laboratories (ABT.N) $38.56 +0.14
Bayer AG (BAYGn.DE) €88.16 +0.01
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.55 -0.51
AstraZeneca plc (AZN.L) 4,037.50p +4.00

Earnings vs. Estimates